Bavarian will market Covid-19 vaccine on its own – but doesn't rule out future partners

In the past, the biotech firm has very publicly stated that partnerships are the way forward regarding its RSV candidate – but when it comes to the firm’s Covid-19 efforts, cards have been kept closer to the chest.
Paul Chaplin, CEO of Bavarian Nordic | Photo: Bavarian Nordic /PR
Paul Chaplin, CEO of Bavarian Nordic | Photo: Bavarian Nordic /PR
by christian bundgaard, translated by daniel pedersen

There’s no shortage of competition on the Covid-19 vaccine market, and things aren’t made easier for Danish biotech firm Bavarian Nordic by competitors being some of the biggest players in the world – remaining so even after a year and some time since the first vaccines against Covid-19 hit the market.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading